[Federal Register: February 4, 1999 (Volume 64, Number 23)] [Notices] [Page 5658] From the Federal Register Online via GPO Access [wais.access.gpo.gov] [DOCID:fr04fe99-59] ======================================================================= ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Scientific Misconduct AGENCY: Office of the Secretary, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has made a final finding of scientific misconduct in the following case: Mr. Thomas Philpot, R.N., B.S.N., Rush-Presbyterian-St. Luke's Medical Center and Northwestern University: Based on the report of an investigation conducted by Rush-Presbyterian-St. Luke's Medical Center (RPMC), a report of an inquiry conducted by Northwestern University, and information obtained by ORI during its oversight review, ORI finds that Mr. Philpot, former data manager for the National Surgical Adjuvant Breast and Bowel Project (NSABP) at RPMC and McNeal Cancer Center, formerly an NSABP affiliate of Northwestern University, engaged in scientific misconduct in clinical research supported by two National Cancer Institute (NCI), National Institutes of Health (NIH) cooperative agreements. Specifically, Mr. Philpot intentionally falsified and/or fabricated follow-up data on seven separate reports related to three patients enrolled in NSABP clinical trials for breast cancer (B-09, B-12, and B- 22). The falsified and/or fabricated data were submitted to the NSABP Biostatistical Center on NSABP reporting forms and were recorded in the NSABP research records maintained at the clinical sites. ORI has implemented the following administrative actions for the three (3) year period beginning January 19, 1999: (1) Mr. Philpot is prohibited from serving in any advisory capacity to PHS, including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant; and (2) any institution that submits an application for PHS support for a research project on which Mr. Philpot's participation is proposed or which uses him in any capacity on PHS supported research, or that submits a report of PHS-funded research in which he is involved, must concurrently submit a plan for supervision of his duties to the funding agency for approval. The supervisory plan must be designed to ensure the scientific integrity of Mr. Philpot's research contribution. The institution also must submit a copy of the supervisory plan to ORI. FOR FURTHER INFORMATION CONTACT: Acting Director, Division of Research Investigations, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443-5330. Chris B. Pascal, Acting Director, Office of Research Integrity. [FR Doc. 99-2616 Filed 2-3-99; 8:45 am] BILLING CODE 4160-17-P